

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 17, 2022 (June 15, 2022)**

**C4 THERAPEUTICS, INC.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39567**

(Commission File Number)

**47-5617627**  
(IRS Employer  
Identification No.)

**490 Arsenal Way, Suite 200**  
**Watertown, MA**  
(Address of Principal Executive Offices)

**02472**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (617) 231-0700**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	CCCC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**Departure of Director**

On June 15, 2022, Alain J. Cohen notified the Board of Directors (the “**Board**”) of C4 Therapeutics, Inc. (the “**Company**”) of his withdrawal as a director nominee for re-election at the 2022 Annual Meeting of Stockholders. The withdrawal was not due to any disagreements with the Company on any matter relating to the Company’s strategy, operations, policies or practices. With his withdrawal, Mr. Cohen will no longer be a nominee for re-election at the Company’s 2022 Annual Meeting of Stockholders and will cease to serve as director and as a member of the Organization, Leadership and Compensation Committee on June 22, 2022. The Board has determined that it will not nominate a replacement director for election at the Company’s 2022 Annual Meeting of Stockholders. In addition, the Board has committed to appoint two gender diverse directors by the date of the Company’s next Annual Meeting of Stockholders.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

C4 Therapeutics, Inc.

Date: June 17, 2022

By: /s/ Lauren A. White

**Lauren A. White**  
**Chief Financial Officer**